LEVETIRACETAM DEXCEL 500

País: Israel

Língua: inglês

Origem: Ministry of Health

Ingredientes ativos:

LEVETIRACETAM

Disponível em:

DEXCEL PHARMA TECHNOLOGIES LTD

Código ATC:

N03AX14

Forma farmacêutica:

TABLETS

Composição:

LEVETIRACETAM 500 MG

Via de administração:

PER OS

Tipo de prescrição:

Required

Fabricado por:

DEXCEL LTD, ISRAEL

Grupo terapêutico:

LEVETIRACETAM

Área terapêutica:

LEVETIRACETAM

Indicações terapêuticas:

Levetiracetam Dexcel is indicated as monotherapy in the treatment of partial onset seizures with or without secondary generalisation in patients from 16 years of age with newly diagnosed epilepsy.Levetiracetam Dexcel is indicated as adjunctive therapy:• In the treatment of partial onset seizures with or without secondary generalisation in adults and children from 4 years of age with epilepsy.• In the treatment of myoclonic seizures in adults and adolescents from 12 years of age with Juvenile Myoclonic Epilepsy.• In the treatment of primary generalised tonic-clonic seizures in adults and adolescents from 12 years of age with Idiopathic Generalised Epilepsy.

Data de autorização:

2018-03-31